Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin

被引：6
|
作者：
Ramagopalan, Sreeram V. [1 ]
Graham, Sophie [2 ]
Carroll, Robert [1 ]
Raluy-Callado, Mireia [2 ]
Nordstrom, Beth L. [3 ]
Donaldson, Robert [2 ]
Colby, Chris [4 ]
Mehmud, Faisal [5 ]
Alikhan, Raza [6 ]
机构：
[1] Bristol Myers Squibb, Ctr Observat Res & Data Sci, Uxbridge UB8 1DH, Middx, England
[2] Evidera, Real World Evidence, London W6 8DL, England
[3] Evidera, Real World Evidence, Waltham, MA 02541 USA
[4] Evidera, Real World Evidence, San Francisco, CA 94111 USA
[5] Bristol Myers Squibb, Uxbridge UB8 1DH, Middx, England
[6] Univ Hosp Wales, Dept Haematol, Cardiff CF14 4XW, S Glam, Wales
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2019年 / 8卷 / 06期
关键词：
NVAF; oral anticoagulants; treatment persistence; RISK-FACTOR; STROKE; DABIGATRAN; THERAPY; SCORE;
D O I：
10.2217/cer-2019-0005
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: Nonvalvular atrial fibrillation (NVAF) requires long-term anticoagulation treatment, which may necessitate frequent primary care visits. Materials & methods: NVAF patients initiating warfarin or apixaban in 2012-2017 were identified from linked primary (Clinical Practice Research Datalink) and secondary care (Hospital Episode Statistics) data. A propensity score matched Cox regression model compared discontinuation risk. Primary care visits were compared via negative binomial regression. Results: A total of 2695 apixaban users were matched to warfarin patients. Discontinuation risk was lower with apixaban than warfarin (hazard ratio: 0.40; 95% CI: 0.35-0.46). Apixaban patients averaged 12.2 annual primary care visits, versus 17.1 for warfarin users (p < 0.001). Conclusion: Apixaban was associated with reduced rates of discontinuation and primary care visits compared with warfarin.
引用
收藏
页码：371 / 379
页数：9
相关论文
共 50 条
  • [1] Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation
    Spivey, Christina A.
    Qiao, Yanru
    Liu, Xianchen
    Mardekian, Jack
    Parker, Robert B.
    Phatak, Hemant
    Claflin, Abigail B.
    Kachroo, Sumesh
    Abdulsattar, Younos
    Chakrabarti, Anwesa
    Wang, Junling
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (07): : 596 - 606
  • [2] Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation
    Carnicelli, Anthony P.
    Al-Khatib, Sana M.
    Xavier, Denis
    Dalgaard, Frederik
    Merrill, Peter D.
    Wojdyla, Daniel M.
    Lewis, Basil S.
    Hanna, Michael
    Alexander, John H.
    Lopes, Renato D.
    Wallentin, Lars
    Granger, Christopher B.
    [J]. HEART, 2021, 107 (09) : 713 - 720
  • [3] DISCONTINUATION AND HEALTH CARE RESOURCE UTILISATION IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH APIXABAN OR WARFARIN IN ENGLAND
    Graham, S.
    Raluy-Callado, M.
    Donaldson, R.
    Colby, C.
    Carroll, R.
    Nordstrom, B.
    Stynes, G.
    Hill, N.
    Ramagopalan, S.
    Alikhan, R.
    [J]. VALUE IN HEALTH, 2018, 21 : S112 - S112
  • [4] APIXABAN COMPARED WITH WARFARIN IN PATIENTS WITH DIABETES AND NONVALVULAR ATRIAL FIBRILLATION IN THE ARISTOTLE TRIAL
    Ezekowitz, Justin A.
    Lewis, Basil
    Lopes, Renato
    Wojdyla, Daniel
    McMurray, John
    Hanna, Michael
    Atar, Dan
    Bahit, Maria
    Keltai, Matyas
    Lopez-Sendon, Jose
    Pais, Prem
    Ruzyllo, Witold
    Wallentin, Lars
    Alexander, John
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A372 - A372
  • [5] Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation
    Pink, J.
    Pirmohamed, M.
    Hughes, D. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 269 - 276
  • [6] Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Coleman, Craig I.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [7] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN FRAIL PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
    Coleman, Craig I.
    Turpie, Alexander
    Bunz, Thomas J.
    Sood, Nitesh
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 290 - 290
  • [8] Warfarin for nonvalvular atrial fibrillation in primary care - another example of the age paradox?
    Burton, CD
    Hamilton, KES
    Isles, CG
    Norrie, J
    [J]. JOURNAL OF CARDIOVASCULAR RISK, 2001, 8 (05): : 307 - 309
  • [9] Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
    Chan, Yi-Hsin
    See, Lai-Chu
    Tu, Hui-Tzu
    Yeh, Yung-Hsin
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    Wang, Chun-Li
    Kuo, Chang-Fu
    Kuo, Chi-Tai
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [10] Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    Bellolio, M. Fernanda
    McBane, Robert D.
    Shah, Nilay D.
    Noseworthy, Peter A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):
12345